Dr. Clay Siegall is a world-renowned scientist and entrepreneur that has worked to develop groundbreaking treatments for a variety of cancers. Specifically, Dr. Siegall works in the field of oncology biotechnology and has created a company that makes great strides towards the treatment of difficult cases in which normal treatments are not effective.
Dr. Clay Siegall is the founder and CEO of Seattle Genetics, the industry leader in the Northwest United States. The most prominent development to come from Seattle Genetics is antibody-drug conjugates or ADCs. These treatments are great for targeting specific conditions with potency and effectiveness. For example, they have, in conjunction with Takeda Pharmaceutical Company, produced ADCetris, which is a treatment used to relapses of Hodgkins Lymphoma. It is currently available in 66 countries. Seattle Genetics is also responsible for creating treatments for both bladder and breast cancer that are giving patients hope for remission.
Dr. Clay Siegall and Seattle Genetics are also on the forefront of another exciting cancer treatment called genome sequencing. It allows scientist the ability to examine each patient’s genetic sequence to determine the best-individualized treatment for them. There are also advancements being used to help detect prostate cancer earlier. These advancements are giving patients hope for a more effective treatment.
Dr. Clay Siegall has worked on the forefront of cancer research for over 20 years and has worked with some of the largest pharmaceutical companies in the world such as Bristol-Meyers Squibb and Ultragenex. He founded Seattle Genetics in 1997 and has served as the CEO since 2002. He also became President of the company in 2000, as well as Executive Vice President and Chief Scientific Officer.He attended George Washington University where he received his Ph. D. in Genetics. He also attended the University of Maryland where he earned a B.S. in Zoology.